Effects of shRNA targeting maspin on invasion of gastric carcinoma SGC7901 cell line

Oncology Reports

Volumn 25, Issue 1, 2011, Pages 259-265

  Yang, Yaying ^a   Shi, Haipeng ^b   Li, Xiujun ^a   Yi, Yongfen ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Chengdu Third People's Hospital   (China)

Author keywords

Gastric carcinoma; Invasion; Maspin; shRNA

Indexed keywords

LIPOFECTAMINE; MASPIN; MATRIGEL; MATRILYSIN; MESSENGER RNA; RECOMBINANT PROTEIN; SHORT HAIRPIN RNA; UROKINASE; VASCULOTROPIN C;

ARTICLE; ASSAY; CANCER CELL CULTURE; CANCER INVASION; CELL COUNT; CLONE; EUKARYOTE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CARCINOMA; VECTOR CONTROL; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; GENE KNOCKDOWN TECHNIQUES; HUMANS; MATRIX METALLOPROTEINASE 7; NEOPLASM INVASIVENESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SERPINS; STOMACH NEOPLASMS; TRANSFECTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 78650754718     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001069     Document Type: Article

References (45)

1. Zou Z, Anisowicz A, Hendrix MJ, et al: Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263: 526-529, 1994.
2. Bailey CM, Khalkhali-Ellis Z, Seftor EA and Hendrix MJ: Biological functions of maspin. J Cell Physiol 209: 617-624, 2006.
3. Lee MJ, Suh CH and Li ZH: Clinicopathological significance of maspin expression in breast cancer. J Korean Med Sci 21: 309-314, 2006.
4. Hall DC, Johnson-Pais TL, Grubbs B, Bernal R, Leach RJ and Padalecki SS: Maspin reduces prostate cancer metastasis to bone. Urol Oncol 26: 652-658, 2008.
5. Yoshizawa K, Nozaki S, Okamune A, et al: Loss of maspin is a negative prognostic factor for invasion and metastasis in oral squamous cell carcinoma. J Oral Pathol Med 38: 535-539, 2009.
6. Chua R, Setzer S, Govindarajan B, Sexton D, Cohen C and Arbiser JL: Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. J Am Acad Dermatol 60: 758-766, 2009.
7. Takanami I, Abiko T and Koizumi S: Expression of maspin in non-small cell lung cancer: correlation with clinical features. Clin Lung Cancer 9: 361-366, 2008.
8. Li HW, Leung SW, Chan CS, Yu MM and Wong YF: Expression of maspin in endometrioid adenocarcinoma of endometrium. Oncol Rep 17: 393-398, 2007.
9. Shi HY, Zhang W, Liang R, Abraham S, Kittrell FS, Medina D and Zhang M: Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Res 61: 6945-6951, 2001.
10. Zhang W, Shi HY and Zhang M: Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC Cancer 5: 50, 2005.
11. McKenzie S, Sakamoto S and Kyprianou N: Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT. Oncogene 27: 7171-7179, 2008.
12. Cella N, Contreras A, Latha K, Rosen JM and Zhang M: Maspin is physically associated with [beta]1 integrin regulating cell adhesion in mammary epithelial cells. FASEB J 20: 1510-1512, 2006.
13. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
14. Shah MA and Kelsen DP: Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw 8: 437-447, 2010.
15. Ito R, Nakayama H, Yoshida K, Oda N and Yasui W: Loss of maspin expression is associated with development and progression of gastric carcinoma with p53 abnormality. Oncol Rep 12: 985-990, 2004.
16. Wang MC, Yang YM, Li XH, Dong F and Li Y: Maspin expression and its clinicopathological significance in tumorigenesis and progression of gastric cancer. World J Gastroenterol 10: 634-637, 2004. (Pubitemid 38351526)
17. Song SY, Son HJ, Kim MH, Nam ES, Rhee JC and Park C: Prognostic significance of maspin expression in human gastric adenocarcinoma. Hepatogastroenterology 54: 973-976, 2007.
18. Terashima M, Maesawa C, Oyama K, et al: Gene expression profiles in human gastric cancer: expression of maspin correlates with lymph node metastasis. Br J Cancer 92: 1130-1136, 2005.
19. Hannon GJ: RNA interference. Nature 418: 244-251, 2002.
20. Lee SH and Sinko PJ: siRNA -getting the message out. Eur J Pharm Sci 27: 401-410, 2006.
21. Gartel AL and Kandel ES: RNA interference in cancer. Biomol Eng 23: 17-34, 2006.
22. Brummelkamp TR, Bernards R and Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553, 2002.
23. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S and Rossi JJ: Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 23: 222-226, 2005.
24. Silverman GA, Bird PI, Carrell RW, et al: The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 276: 33293-33296, 2001.
25. Ngamkitidechakul C, Warejcka DJ, Burke JM, O'Brien WJ and Twining SS: Sufficiency of the reactive site loop of maspin for induction of cell-matrix adhesion and inhibition of cell invasion. Conversion of ovalbumin to a maspin-like molecule. J Biol Chem 278: 31796-31806, 2003.
26. Law RH, Irving JA, Buckle AM, et al: The high resolution crystal structure of the human tumor suppressor maspin reveals a novel conformational switch in the G-helix. J Biol Chem 280: 22356-22364, 2005.
27. Biliran H Jr and Sheng S: Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 61: 8676-8682, 2001.
28. Yin S, Lockett J, Meng Y, et al: Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Cancer Res 66: 4173-4181, 2006.
29. Jo M, Thomas KS, Wu L and Gonias SL: Soluble urokinasetype plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. J Biol Chem 278: 46692-46698, 2003.
30. Amir S, Margaryan NV, Odero-Marah V, Khalkhali-Ellis Z and Hendrix MJ: Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells. Cancer Biol Ther 4: 400-406, 2005.
31. Zhang M, Volpert O, Shi YH, et al: Maspin is an angiogenesis inhibitor. Nat Med 6: 196-199, 2000.
32. Nickoloff BJ, Lingen MW, Chang BD, et al: Tumor suppressor maspin is up-regulated during keratinocyte senescence, exerting a paracrine antiangiogenic activity. Cancer Res 64: 2956-2961, 2004.
33. Li JJ, Chen Y, Zhang SM, Wu DY, Wang YP and Xin Y: Pathobiological significance of vascular endothelial growth factor and Maspin expressions in human gastric carcinoma. World J Gastroenterol 10: 2624-2627, 2004.
34. Giatromanolaki A, Koukourakis MI, Stathopoulos GP, et al: Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer. Oncol Res 12: 33-41, 2000.
35. Yonemura Y, Endo Y, Fujita H, et al: Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 5: 1823-1829, 1999.
36. Ishikawa M, Kitayama J, Kazama S, et al: Expresson of vascular endothelial growth factor C and D (VEGF-C and D) is an important risk factor for lymphatic metastasis in undifferentiated early gastric carcinoma. Jpn J Clin Oncol 33: 21-27, 2003.
37. Aihara R, Mochiki E, Nakabayashi T, Akazawa K, Asao T and Kuwano H: Clinical significance of mucin phenotype, betacatenin and matrix metalloproteinase 7 in early undifferentiated gastric carcinoma. Br J Surg 92: 454-462, 2005.
38. Adachi Y, Itoh F, Yamamoto H, Iku S, Matsuno K, Arimura Y and Imai K: Retinoic acids reduce matrilysin (matrix metalloproteinase 7) and inhibit tumor cell invasion in human colon cancer. Tumour Biol 22: 247-253, 2001.
39. Yamamoto H, Iku S, Adachi Y, Imsumran A, et al: Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J Pathol 199: 176-184, 2003.
40. Yamamoto H, Horiuchi S, Adachi Y, Taniguchi H, Nosho K, Min Y and Imai K: Expression of ets-related transcriptional factor E1AF is associated with tumor progression and overexpression of matrilysin in human gastric cancer. Carcinogenesis 25: 325-332, 2004.
41. Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP and Boyd MT: Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 10: 2832-2845, 2004.
42. Okayama H, Kumamoto K, Saitou K, et al: CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep 22: 745-755, 2009.
43. Cebrahem Q, Chaurasia SS, Vasanji A, et al: Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am J Pathol 176: 496-503, 2010.
44. Wang FQ, So J, Reierstad S, et al: Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer 114: 19-31, 2005.
45. Murphy G, Stanton H, Cowell S, et al: Mechanisms for pro matrix metalloproteinase activation. APMIS 107: 38-44, 1999.